Jefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at ChardanOctober 6, 2016 7:39 AM Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy WeaknessOctober 6, 2016 7:26 AM Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'October 6, 2016 7:23 AM Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam SetbackOctober 6, 2016 6:44 AM JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to NeutralOctober 6, 2016 6:41 AM Barclays Downgrades Alnylam Pharmaceuticals (ALNY) to EqualweightOctober 6, 2016 6:41 AM Leerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market PerformOctober 6, 2016 6:39 AM BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam FailureOctober 6, 2016 6:29 AM Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect PatisiranOctober 5, 2016 4:31 PM Alnylam Pharmaceuticals Discontinues Revusiran DevelopmentOctober 5, 2016 4:30 PM